Financings in Brief: Somanetics
This article was originally published in The Gray Sheet
Executive SummarySomanetics: Extends redemption date of its Class B warrants from August 4, 1995 to November 8, 1995. The Troy, Michigan-based developer of the Cerebral Oximeter monitoring system recently grossed $1.9 mil. in a placement of 750,000 units for $2.50 each. The units placed consist of two common shares and one warrant to buy a common share for $2 before July 13, 2000. Somanetics says net proceeds from the offering will be used "to sustain its operations, including clinical research and selling and marketing efforts; to fund its losses; and for working capital purposes, including increased accounts receivable and inventories"...
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.